Breaking Finance News

A statement released earlier today by Chardan Capital about Dicerna Pharmaceuticals (NASDAQ:DRNA) bumps down the target price to $3.50

Chardan Capital lowered the price target of Dicerna Pharmaceuticals (NASDAQ:DRNA) to $4, indicating a possible upside of 0.01%.

On Monday August 8 2016, Chardan Capital released a statement on Dicerna Pharmaceuticals(NASDAQ:DRNA) lowered the target price from $4.00 to $3.50 that indicated a possible upside of 0.04%.

Only yesterday Dicerna Pharmaceuticals (NASDAQ:DRNA) traded 3.12% higher at $3.45. Dicerna Pharmaceuticals’s 50-day average is $3.33 and its two hundred day moving average is $4.01. The last stock price is down 17.55% relative to the 200-day average, compared with the S&P 500 Index which has fallen -0.01% over the same time period. Trading volume was was down over the average, with 105,282 shares of DRNA changing hands under the typical 268,411 shares..

See Graph Below:

Dicerna Pharmaceuticals (NASDAQ:DRNA)

With a market cap of $0.0, Dicerna Pharmaceuticals has a one-year low of $2.69 and a 52 week high of $15.93 with a PE ratio of 0.

In addition to Chardan Capital reporting it’s price target, a total of 4 brokerages have reported on the stock. The consensus target price is $14.50 with three analysts rating the stock a strong buy, one firm rating the stock a buy, one firm rating the stock a hold, 0 rating the company to underperform, and finally 0 brokeragesrating the stock as sell.

Brief Synopsis On Dicerna Pharmaceuticals (NASDAQ:DRNA)

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, and including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *